Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D1C0WB
|
|||
| Drug Name |
DZD1516
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | HER2-positive breast cancer [ICD-11: 2C60-2C65] | Phase 1 | [1] | |
| Company |
Dizal Pharmaceuticals
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT04509596) DZD1516 in Combination With Trastuzumab and Capecitabine, or in Combination With T-DM1, in Patients With Metastatic HER2 Positive Breast Cancer. U.S. National Institutes of Health. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.